Pharmaceutical manufacturer Sanofi has announced that the U.S. Food and Drug Administration (FGA) has granted Breakthrough Therapy Designation to Cemiplimab (REGN2810) as a treatment for adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC.

Breakthrough Therapy Designation is granted to drugs aimed at treating serious or life-threatening conditions, either alone or in combination with another medication, with the aim of speeding up the development of these vital medicines. It may also be granted when preliminary clinical evidence suggests the drug may be substantially more effective than existing treatments. Other drugs to be granted this status in 2017 include Nivolumab for the treatment of urothelial carcinoma, Pembrolizumab for the treatment of Hodgkin Lymphoma, and Dupilumab, used for treating atopic dermatitis.

Cemiplimab is an investigation human monoclonal antibody targeting PD-1 and is currently in the second phase of clinical trials. Following a Phase 1 study of around 400 patients, Sanofi and Regeneron reported positive preliminary results and are in the process of enrolling patients for a Phase 2 trial.

In a statement announcing the latest development, Sanofi asserted: "Although CSCC has a good prognosis when caught early, it can prove especially difficult to treat when it progresses to advanced stages."

According to the American Cancer Society, skin cancer is the most commonly diagnosed form of cancer in the United States. CSCC is one of the main forms of skin cancer and usually manifests as a hard lump with a scaly top. The highest risk factor is exposure to ultraviolet radiation from the sun. It is often treated with surgical removal, radiation therapy, and chemotherapy. CSCC is the second most common form of skin cancer after nonmelanoma skin cancer.

RxSpark

RxSpark is an easy-to-use platform offering huge savings on prescriptions and helping Americans save up to 80% on prescriptions and over-the-counter medication. The price of medication varies significantly between pharmacies, and many patients never realize there are better prices available online than at their local pharmacy. RxSpark offers online discounts on an extensive range of pharmacy products. We help you find the best prices at pharmacies across the country, so you get the prescriptions and over-the-counter medications you need, at a price you can afford.

Partners

DISCOUNT ONLY – NOT INSURANCE. RxSpark solely promotes discounts and does not provide insurance of any kind. Discounts are available exclusively through participating pharmacies. The range of the discounts will vary depending on the type of provider and services rendered. This program does not make payments directly to providers. Members are required to pay for all healthcare services. You may cancel your registration at any time or file a complaint by contacting Customer Care. This program is administered for RxSpark by Medical Security Card Company, LLC of Tucson, AZ. Average savings of 45% with potential savings of up to 80%. (based on 2016 national program savings data). All prescription drugs are eligible for savings. Prescriptions paid for in whole or in part by third party or government funded healthcare programs, such as Medicare and Medicaid, are ineligible.

For every friend or family member you refer, you will earn 100 reward points on their first prescription purchase! Plus you earn reward points on every prescription purchase they make with their RxSpark card.